SK bioscience

At SK bioscience, we work everyday to promote human health from prevetion to cure. We have successfully developed South Koreas first COVID-19 vaccine, SKYCovione through global cooperation with the Bill & Melinda Gates Foundation, CEPI, GSK, etc., and a universal vaccine to prevent Sarbecovirus. We have also developed the worlds first quadrivalent cell-cultured influenza vaccine, SKYCellflu with obtaining WHO PQ (Pre-qualification) certification in 2019 followed by developing SKYZoster, the worlds second shingles vaccine, and SkyVaricella, the worlds second WHO PQ-certified chickenpox vaccine. We are expanding our R&D pipeline through global partnerships with public and private institutions, and is planning to commercialize a pneumococcal conjugate vaccine, cervical cancer vaccine, typhoid conjugate vaccine, and rotavirus vaccine. In addition, SK bioscience signed a CMO contract to manufacture AstraZenecas COVID-19 vaccine from drug substance to drug product at L-House, SK biosci...